{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T07:45:23Z","timestamp":1778658323567,"version":"3.51.4"},"reference-count":44,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T00:00:00Z","timestamp":1620691200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Centre de recherche du CHUS"},{"name":"Foundation of the Stars"},{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Fragile X syndrome (FXS) is the leading inherited cause of intellectual disability and is caused by the loss of expression of the Fragile X mental retardation protein (FMRP). In animal model of FXS, the absence of FMRP leads to an aberrant rate of neuronal protein synthesis, which in turn is believed to be at the origin of defects regarding spine morphology and synaptic plasticity. Normalisation of protein synthesis in these models has been associated with a rescue of FXS behavioral and biochemicals phenotype, thus establishing the rate of protein synthesis as one of the most promising monitoring biomarker for FXS. However, rate of protein synthesis alteration in fragile X individuals is not well characterized.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Method<\/jats:title>\n<jats:p>We applied a robust radiolabeled assay to measure rate of protein synthesis in freshly extracted peripheral blood mononuclear cells (PBMCs) and blood platelets. We ultimately settle on PBMCs to measure and compare rate of protein synthesis in 13 males with fragile X and 14 matched controls individuals.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Using this method, we measured a 26.9% decrease (p = 0,0193) in the rate of protein synthesis in fragile X individuals PBMCs. Furthermore, the rate of protein synthesis measurements obtained were highly reproducible, highlighting the robustness of the method.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Our work presents the first evidence of a diminution of the rate of protein synthesis in a human peripheral model of fragile X. Our results also support the finding of previous studies using brain PET imaging in Fragile X individuals. Since our assay only requires a simple venous puncture, it could be used in other cases of intellectual disability in order to determine if an aberrant rate of protein synthesis is a common general mechanism leading to impairment in synaptic plasticity and to intellectual disability.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0251367","type":"journal-article","created":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T17:30:09Z","timestamp":1620754209000},"page":"e0251367","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":13,"title":["Rates of protein synthesis are reduced in peripheral blood mononuclear cells (PBMCs) from fragile X individuals"],"prefix":"10.1371","volume":"16","author":[{"given":"Olivier","family":"Dionne","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audrey","family":"Lortie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Gagnon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7712-5897","authenticated-orcid":true,"given":"Fran\u00e7ois","family":"Corbin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2021,5,11]]},"reference":[{"key":"pone.0251367.ref001","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.ajhg.2009.09.007","article-title":"Incidence of Fragile X Syndrome by Newborn Screening for Methylated FMR1 DNA","volume":"85","author":"B Coffee","year":"2009","journal-title":"The American Journal of Human Genetics"},{"key":"pone.0251367.ref002","doi-asserted-by":"crossref","DOI":"10.1186\/s13052-017-0355-y","article-title":"Fragile X syndrome: a review of clinical and molecular diagnoses","volume":"43","author":"C Ciaccio","year":"2017","journal-title":"Ital J Pediatr"},{"key":"pone.0251367.ref003","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1542\/peds.2013-4301","article-title":"Fragile X Syndrome: A Review of Associated Medical Problems","volume":"134","author":"SA Kidd","year":"2014","journal-title":"Pediatrics"},{"key":"pone.0251367.ref004","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1126\/science.1245831","article-title":"Promoter-bound trinucleotide repeat mRNA drives epigenetic silencing in fragile X syndrome","volume":"343","author":"D Colak","year":"2014","journal-title":"Science"},{"key":"pone.0251367.ref005","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/0092-8674(91)90125-I","article-title":"Absence of expression of the FMR-1 gene in fragile X syndrome","volume":"66","author":"M Pieretti","year":"1991","journal-title":"Cell"},{"key":"pone.0251367.ref006","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/0092-8674(91)90397-H","article-title":"Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome","volume":"65","author":"AJMH Verkerk","year":"1991","journal-title":"Cell"},{"key":"pone.0251367.ref007","first-page":"14","volume":"77","author":"EW Khandjian","year":"1999","journal-title":"Biology of the fragile X mental retardation protein, an RNA-binding protein"},{"key":"pone.0251367.ref008","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.biochi.2011.12.014","article-title":"Unusual subcellular confinement of the fragile X mental retardation protein (FMRP) in circulating human platelets: Complete polyribosome dissociation","volume":"94","author":"V Lauzi\u00e8re","year":"2012","journal-title":"Biochimie"},{"key":"pone.0251367.ref009","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1093\/hmg\/6.9.1465","article-title":"The fragile X mental retardation protein is associated with poly(A)+ mRNA in actively translating polyribosomes","volume":"6","author":"F Corbin","year":"1997","journal-title":"Human Molecular Genetics"},{"key":"pone.0251367.ref010","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0092-8674(01)00568-2","article-title":"Microarray identification of FMRP-associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome","volume":"107","author":"V Brown","year":"2001","journal-title":"Cell"},{"key":"pone.0251367.ref011","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.cell.2011.06.013","article-title":"FMRP Stalls Ribosomal Translocation on mRNAs Linked to Synaptic Function and Autism","volume":"146","author":"JC Darnell","year":"2011","journal-title":"Cell"},{"key":"pone.0251367.ref012","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3389\/fmolb.2018.00113","article-title":"Fragile X Mental Retardation Protein: To Be or Not to Be a Translational Enhancer","volume":"5","author":"T Maurin","year":"2018","journal-title":"Frontiers in Molecular Biosciences"},{"key":"pone.0251367.ref013","doi-asserted-by":"crossref","first-page":"5087","DOI":"10.1523\/JNEUROSCI.0093-05.2005","article-title":"Postadolescent changes in regional cerebral protein synthesis: an in vivo study in the FMR1 null mouse","volume":"25","author":"M Qin","year":"2005","journal-title":"J Neurosci"},{"key":"pone.0251367.ref014","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-09553-8","article-title":"Altered steady state and activity-dependent de novo protein expression in fragile X syndrome","volume":"10","author":"H Bowling","year":"2019","journal-title":"Nat Commun"},{"key":"pone.0251367.ref015","doi-asserted-by":"crossref","first-page":"15616","DOI":"10.1523\/JNEUROSCI.3888-10.2010","article-title":"Hypersensitivity to mGluR5 and ERK1\/2 Leads to Excessive Protein Synthesis in the Hippocampus of a Mouse Model of Fragile X Syndrome","volume":"30","author":"EK Osterweil","year":"2010","journal-title":"Journal of Neuroscience"},{"key":"pone.0251367.ref016","doi-asserted-by":"crossref","first-page":"10624","DOI":"10.1523\/JNEUROSCI.0402-10.2010","article-title":"Excess Phosphoinositide 3-Kinase Subunit Synthesis and Activity as a Novel Therapeutic Target in Fragile X Syndrome","volume":"30","author":"C Gross","year":"2010","journal-title":"Journal of Neuroscience"},{"key":"pone.0251367.ref017","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.neuron.2012.03.009","article-title":"Chronic Pharmacological mGlu5 Inhibition Corrects Fragile X in Adult Mice","volume":"74","author":"A Michalon","year":"2012","journal-title":"Neuron"},{"key":"pone.0251367.ref018","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.celrep.2015.03.065","article-title":"Selective Role of the Catalytic PI3K Subunit p110\u03b2 in Impaired Higher Order Cognition in Fragile X Syndrome","volume":"11","author":"C Gross","year":"2015","journal-title":"Cell Reports"},{"key":"pone.0251367.ref019","doi-asserted-by":"crossref","first-page":"152ra128","DOI":"10.1126\/scitranslmed.3004218","article-title":"Reversal of Disease-Related Pathologies in the Fragile X Mouse Model by Selective Activation of GABAB Receptors with Arbaclofen","volume":"4","author":"C Henderson","year":"2012","journal-title":"Science Translational Medicine"},{"key":"pone.0251367.ref020","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nm.4335","article-title":"Metformin ameliorates core deficits in a mouse model of fragile X syndrome","volume":"23","author":"I Gantois","year":"2017","journal-title":"Nature Medicine"},{"key":"pone.0251367.ref021","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.neuron.2012.01.034","article-title":"Lovastatin Corrects Excess Protein Synthesis and Prevents Epileptogenesis in a Mouse Model of Fragile X Syndrome","volume":"77","author":"EK Osterweil","year":"2013","journal-title":"Neuron"},{"key":"pone.0251367.ref022","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.neuron.2007.12.001","article-title":"Correction of Fragile X Syndrome in Mice","volume":"56","author":"G D\u00f6len","year":"2007","journal-title":"Neuron"},{"key":"pone.0251367.ref023","doi-asserted-by":"crossref","first-page":"e1000016","DOI":"10.1371\/journal.pbio.1000016","article-title":"A Novel Function for Fragile X Mental Retardation Protein in Translational Activation. Wickens M, editor","volume":"7","author":"EG Bechara","year":"2009","journal-title":"PLoS Biology"},{"key":"pone.0251367.ref024","first-page":"499","article-title":"Altered Cerebral Protein Synthesis in Fragile X Syndrome: Studies in Human Subjects and Knockout Mice. Journal of Cerebral Blood Flow &","volume":"33","author":"M Qin","year":"2013","journal-title":"Metabolism"},{"key":"pone.0251367.ref025","doi-asserted-by":"crossref","first-page":"104978","DOI":"10.1016\/j.nbd.2020.104978","article-title":"Regional rates of brain protein synthesis are unaltered in dexmedetomidine sedated young men with fragile X syndrome: A L-[1-11C]leucine PET study","volume":"143","author":"KC Schmidt","year":"2020","journal-title":"Neurobiology of Disease"},{"key":"pone.0251367.ref026","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3389\/fnmol.2018.00041","article-title":"Of Men and Mice: Modeling the Fragile X Syndrome","volume":"11","author":"R Dahlhaus","year":"2018","journal-title":"Front Mol Neurosci"},{"key":"pone.0251367.ref027","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1203\/00006450-199511000-00002","article-title":"Reduced Cyclic AMP Production in Fragile X Syndrome: Cytogenetic and Molecular Correlations","volume":"38","author":"E Berry-Kravis","year":"1995","journal-title":"Pediatr Res"},{"key":"pone.0251367.ref028","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/j.1601-183X.2012.00768.x","article-title":"Altered mTOR signaling and enhanced CYFIP2 expression levels in subjects with Fragile X syndrome","volume":"11","author":"CA Hoeffer","year":"2012","journal-title":"Genes Brain Behav"},{"key":"pone.0251367.ref029","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1866-1955-5-8","article-title":"A quantitative homogeneous assay for fragile X mental retardation 1 protein","volume":"5","author":"G Schutzius","year":"2013","journal-title":"Journal of Neurodevelopmental Disorders"},{"key":"pone.0251367.ref030","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1002\/ajmg.b.30765","article-title":"Early-phase ERK activation as a biomarker for metabolic status in fragile X syndrome. American Journal of Medical Genetics Part B","volume":"147B","author":"N Weng","year":"2008","journal-title":"Neuropsychiatric Genetics"},{"key":"pone.0251367.ref031","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/ajmg.1320450120","article-title":"Demonstration of abnormal cyclic AMP production in platelets from patients with fragile X syndrome","volume":"45","author":"E Berry\u2010Kravis","year":"1993","journal-title":"American Journal of Medical Genetics"},{"key":"pone.0251367.ref032","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/j.1399-0004.2011.01798.x","article-title":"Quantitative measurement of FMRP in blood platelets as a new screening test for fragile X syndrome","volume":"82","author":"M Lessard","year":"2012","journal-title":"Clinical Genetics"},{"key":"pone.0251367.ref033","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/09537104.2017.1317733","article-title":"Platelets as a surrogate disease model of neurodevelopmental disorders: Insights from Fragile X Syndrome","volume":"29","author":"D Pellerin","year":"2018","journal-title":"Platelets"},{"key":"pone.0251367.ref034","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3109\/1354750X.2016.1160289","article-title":"Lovastatin corrects ERK pathway hyperactivation in fragile X syndrome: potential of platelet\u2019s signaling cascades as new outcome measures in clinical trials","volume":"21","author":"D Pellerin","year":"2016","journal-title":"Biomarkers"},{"key":"pone.0251367.ref035","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1037\/1040-3590.19.2.236","article-title":"Wechsler Adult Intelligence Scale-Third Edition short form for index and IQ scores in a psychiatric population","volume":"19","author":"BK Christensen","year":"2007","journal-title":"Psychological Assessment"},{"key":"pone.0251367.ref036","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1007\/s10803-011-1370-2","article-title":"Psychometric study of the Aberrant Behavior Checklist in Fragile X Syndrome and implications for targeted treatment","volume":"42","author":"SM Sansone","year":"2012","journal-title":"J Autism Dev Disord"},{"key":"pone.0251367.ref037","volume-title":"Adaptive Behavior Assessment System\u2014Second edition (ABAS-II)","author":"P Harrison","year":"2003"},{"key":"pone.0251367.ref038","volume-title":"BRIEF-A: Behavior rating inventory of executive function-adult version: Professional manual","author":"R Roth","year":"2005"},{"key":"pone.0251367.ref039","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/s41596-018-0100-z","article-title":"Cell-type-specific quantification of protein synthesis in vivo","volume":"14","author":"L Hidalgo San Jose","year":"2019","journal-title":"Nature Protocols"},{"key":"pone.0251367.ref040","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1538-7836.2008.03211.x","article-title":"Protein Synthesis by Platelets: Historical and New Perspectives","volume":"7","author":"AS Weyrich","year":"2009","journal-title":"J Thromb Haemost"},{"key":"pone.0251367.ref041","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1423-0410.2010.01333.x","article-title":"De novo protein synthesis in mature platelets: a consideration for transfusion medicine","volume":"99","author":"P Schubert","year":"2010","journal-title":"Vox Sanguinis"},{"key":"pone.0251367.ref042","article-title":"Modelling Protein Synthesis as A Biomarker in Fragile X Syndrome Patient-Derived Cells","volume":"9","author":"R Pal","year":"2019","journal-title":"Brain Sci"},{"key":"pone.0251367.ref043","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1093\/hmg\/ddy099","article-title":"Protein synthesis levels are increased in a subset of individuals with fragile X syndrome","volume":"27","author":"S Jacquemont","year":"2018","journal-title":"Hum Mol Genet"},{"key":"pone.0251367.ref044","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40348-014-0001-3","article-title":"The quest for fragile X biomarkers","volume":"1","author":"CJ Westmark","year":"2014","journal-title":"Molecular and Cellular Pediatrics"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0251367","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T17:30:50Z","timestamp":1620754250000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0251367"}},"subtitle":[],"editor":[{"given":"Thierry","family":"Rabilloud","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,5,11]]},"references-count":44,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,5,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0251367","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,11]]}}}